,title,selftext,time,tickers
0,Long $TSLA,,2018-01-01 13:44:21,['TSLA']
0,"Saw this chart, instantly thought of this sub. Long $RAD",,2018-01-02 00:55:26,['RAD']
0,"talk about a big start to the new year - a behemoth sold 16626 $MNK april $17.5 puts at $1.50 right at the open this morning. that‚Äôs a $2,500,000 long position for those of you that don‚Äôt math",,2018-01-02 20:35:13,['MNK']
0,Long $XXII,,2018-01-05 15:08:23,['XXII']
0,Long $AMZN,,2018-01-07 00:30:22,['AMZN']
0,"Solid $APPL DD: ""Apple stock price will double in the very long term because of technology in the iPhone X"" and ""Investors like round numbers, therefore the stock is going to $200""",[deleted],2018-01-08 00:21:43,['APPL']
0,Catching the $MARK train,Once again $MARK is chugging along like a champion.,2018-01-08 11:14:45,['MARK']
0,$AC - board your flight,"Poised for a quick pick-up after a slight drop in altitude today. The stock has hit some turbulence but the captain will steady the price and soar even higher. Won't take too long either.


My DD is these flight puns.",2018-01-08 14:25:45,['AC']
0,"Pfizer turning into a bank, and everyone knows banks make money. Time to go long $PFE",,2018-01-09 12:12:34,['PFE']
0,Long $FNKO DD inside,,2018-01-10 14:34:24,['FNKO']
0,Long $WU,[removed],2018-01-11 10:46:45,['WU']
0,DD: Intercept Pharma $ICPT,"Alright, first DD ever. Let me know if I'm a faggot because I'm still trying to decide.

Back in 2016 after their first drug called Ocaliva was on the market, 19 people died, but those people were dying either way. PBC is a bitch. Doctors were giving bad doses, people were starting the meds sick as fuck already, and with better education between the company and the doctors, they'd have been fine. I imagine they've learned this. Basically, though, the drug wasn't what killed people. Nonetheless, investors freaked out and in September it dropped 50%. The company is still working on that PBC treatment but also, more importantly, a treatment for NASH. NASH is a currently untreatable liver disease that is common and growing across the globe, affecting 2%- 5% of the USA. 

So if you get in now, it's undervalued and set to go pretty high if their trials go well. This is probably a long to some extent but I believe it could be very good.",2018-01-11 23:42:28,['ICPT']
0,Any one else long $DVN,Anyone else playin oil or is it beneath y‚Äôall ,2018-01-12 10:03:20,['DVN']
0,"Today‚Äôs $MRK call move might be related to the massive put selling not too long ago. Trader bought just over 3,700 April $60 calls at about $4.50. About a $1.6 million position",,2018-01-16 17:22:46,['MRK']
0,First 7 Months Trading Results - Long $SNAP,[deleted],2018-01-17 06:31:27,['SNAP']
0,Long $MAZDA,,2018-01-17 21:40:56,['MAZDA']
0,Long $UVXY,Always bank on US gov dysfunction.,2018-01-19 23:18:57,['UVXY']
0,long infrastructure $MLM DD,[deleted],2018-01-20 21:18:01,['MLM']
0,Long $CAT for earnings. (Insider info),,2018-01-22 11:26:06,['CAT']
0,Long $AMD,,2018-01-22 15:21:20,['AMD']
0,Long $ROKU,My dad works at Nvidia and we just bought a Roku system and it's up 8%. Buy now before it crashes 6% on Wednesday.,2018-01-22 16:36:25,['ROKU']
0,Long $JNJ,"Just do it.

Looking like $151 target.

Historic earning look great on dailies.

Cheap ass ITM options @ 1.71, most of the volume is @ 152.5 on weekly expiring the 26th.

Current price $148.",2018-01-22 22:46:00,['JNJ']
0,Long $NFLX,,2018-01-23 08:03:21,['NFLX']
0,Long $FB,,2018-01-24 04:34:27,['FB']
0,Long $MATW,People are literally dying to buy their products ,2018-01-24 04:36:34,['MATW']
0,Long $TRXC $SQM $FMC $JNJ $NVAX $OMER,[removed],2018-01-24 04:56:59,"['TRXC', 'SQM', 'FMC', 'NVAX', 'OMER']"
0,$NTNX,"Nutanix is an amazing company. Met some of the folks there at a conference called NSDI. They are growing fast and customers like their product. They are taking away Vmware's market share, so much so that vmware resorted to some real dirty smirking campaign. 
Stock is down quite a bit today due to note saying XYZ priced in but as we saw with Square, people love growth. Might be a good time to add a long position.",2018-01-25 11:46:01,['NTNX']
0,Long $ULTA and $EL,,2018-01-25 20:06:12,"['ULTA', 'EL']"
0,Super Long $Amd and $nvda this is getting crazy,,2018-01-26 18:34:54,['A']
0,Long $Hip $Hop,[deleted],2018-01-28 22:29:38,['H']
0,Long $YINN (DD inside),[removed],2018-01-29 08:34:48,['YINN']
0,Long $MJX DD inside,,2018-02-01 21:48:28,['MJX']
0,Riding that $SNE wave for the long hold,[deleted],2018-02-02 09:04:35,['SNE']
0,Long $GPRO,,2018-02-02 15:51:46,['GPRO']
0,This sub is the reason I didn‚Äôt long $ROPE today...,[removed],2018-02-05 16:24:24,['ROPE']
0,Long $SNAP and long Father $ELON,,2018-02-07 01:48:08,['ELON']
0,Long $MUSK family,,2018-02-07 10:35:03,['MUSK']
0,$NVDA long lost lil bro $BOTZ,[removed],2018-02-08 17:35:35,"['NVDA', 'BOTZ']"
0,Long $AAPL DD inside,,2018-02-11 10:11:46,['AAPL']
0,Long $XIV,,2018-02-11 18:46:52,['XIV']
0,Long $MNECRFT DD inside,[deleted],2018-02-14 16:15:20,['MNECRFT']
0,Long $MCD tendies inside,,2018-02-14 17:23:55,['MCD']
0,Long $SQ,[deleted],2018-02-14 22:46:00,['SQ']
0,$WM advertising strategies are cutting edge. Innovative. Long $WM.,,2018-02-16 15:04:45,['WM']
0,Trailer is out for Jack Ma's movie debut. Long $BABA,,2018-02-18 17:00:00,['BABA']
0,Long $UAL they be talkin bout tendie$,,2018-02-21 18:00:53,['UAL']
0,Chipotle adding quinoa to their menu. Trendy AF. Long $CMG!,,2018-02-21 18:58:37,['CMG']
0,Long $TWTR [DD inside],[deleted],2018-02-22 20:17:13,['TWTR']
0,Why shouldn't I buy $UBQT,"Great products, investing in R&amp;D so potential for long term growth, pretty decent dip from historical highs and wallstreetbets isn't shilling it (yet) 

EDIT: I mean UBNT god damn it",2018-02-26 14:00:29,['UBQT']
0,$RTN long term play,Good defense stock that I can see 10-20% in the next 6 months. This would not be a swing trade.,2018-02-27 12:43:25,['RTN']
0,Long $WWE,"When terror goes up, so do entertainment escapes. The incoming potential nuclear war means lots of terror. You do the math ",2018-02-28 00:39:15,['WWE']
0,Long $YUM,NFL names Pizza Hut official pizza company of the league. ,2018-02-28 16:51:50,['YUM']
0,Now is the time for all great autists to finally long COAL,$HCC to the moon!  This shit is so beat up from all coal hatred people forgot you actually need coal to make steel and aluminium,2018-03-01 14:14:10,['HCC']
0,Long $AMTD DD INSIDE,,2018-03-01 16:21:05,['AMTD']
0,Long $DFEN; Putin wants Cold War II.,,2018-03-01 21:25:01,['DFEN']
0,Flat is the new green,"Happy Friday y'all,  one market secret I found was that if you expect to be down 1% every day, you sure can handle losses in a much better manner. 

For example, im only down $300 and feel on top of the world. Please cue market sell off now. 

Update: market gods persuaded me to take a very sizable position long $SVXY, will close out by end of day. Godspeed.",2018-03-02 10:35:10,['SVXY']
0,$LRCX has ‚Äúanalyst day‚Äù next Tuesday,Which is why its prob up today. Seems like easy money into Tues morning long at least regardless of what market does. ,2018-03-02 14:51:48,['LRCX']
0,Doing my part guys! Long $MU!,,2018-03-03 15:26:43,['MU']
0,Long $BNJ,,2018-03-04 21:34:45,['BNJ']
0,"Skynet. $LMT pitching space craft, lasers, etf to Dept of Defense","https://www.cnbc.com/2018/03/06/future-weapons-lockheed-martin-pitches-new-war-tech-to-pentagon.html

&gt; Hypersonic planes, lasers that burn drones out of the sky, and machines that mimic the human brain once seemed like technologies on the fringes of science fiction.

&gt; Yet several defense contractors are developing these engineering concepts for the U.S. military, hoping to get a piece of what is surely going to be a lucrative and lengthy contract.

&gt; This week, Lockheed Martin's CEO touted investments in hypersonics, laser weapons, electronic warfare and artificial intelligence

Long AF $LMT $RTN $NOC ",2018-03-06 10:37:36,"['LMT', 'NOC']"
0,Long $DIS DD Inside,,2018-03-06 12:57:46,['DIS']
0,Long $BB,,2018-03-08 03:33:44,['BB']
0,$BIDU LONG LONG LONG,This company will be the next Netflix. I'm waiting for a small dip in the next few days and going long ,2018-03-09 13:08:45,['BIDU']
0,Long $BA and $RTN,"These stocks are going to continue to rally hard through 2018.

Thank you,

Tom Culllen",2018-03-09 14:49:02,['BA']
0,Long NL Industries ($NL),[removed],2018-03-16 17:24:59,['NL']
0,Long $CROX. DD on Discord.,"Hello fellow autistics. I am writing to inform you that $CROX, the manufacturer of fine footwear and 'Jibbit' accessories will be going to the moon. Long $CROX

Price target of $17 by 7/1/2018.",2018-03-20 10:16:49,['CROX']
0,Another shooting. You know what that means.,"https://www.cnn.com/2018/03/20/us/great-mills-high-school-shooting/index.html

Long $RGR $SWHC",2018-03-20 13:12:57,"['RGR', 'SWHC']"
0,$GIS - Long before the bell into earnings,"Massive upside here of at least 21% even with the most conservative numbers. I'm inputing a long term revenue *decline* over 5 years into my model, with a corresponding decline in EBIT and cash flows, and the fair value is still $60. With realistic growth forecasts the fair value is easily in the 80s.

Analyst forecasts for Q3 are pretty modest, so a beat shouldn't be difficult and even with a miss there really isn't any place to go. With the stock already trading at a hard resistance line, it would likely recover quickly if it moved down at all.

Set your alarm and wake up before ER to buy this one. I took a bull spread before market close. ",2018-03-20 23:32:14,['GIS']
0,Look into the $WYNN dip today (Brief DD),"Steve is now only the 3rd largest shareholder to avoid public scrutiny from the gaming comissions. The company will either be aquired or Elaine Wynn may take a more active role. The Q1 numbers are supposed to be great for a shorter term play and the projects in progress (Boston Harbor Casino) make this a promising long term prospect.

I bought calls recently and have been holding shares since 164

Everything is on sale today, go make some money.",2018-03-22 11:29:49,['WYNN']
0,"My reaction today, being long $ABBV and after selling SPY 270 puts for a loss yesterday.",,2018-03-22 16:27:49,['ABBV']
0,Long $AOI (DD inside),"Canada passed some legislation...stocks up 17% after-hours. Last time it was up AH, stock ripped next day to $30. 

",2018-03-22 20:13:18,['AOI']
0,FUCK THIS SHIT ! Long $VXX,[removed],2018-03-23 15:20:04,['VXX']
0,$LULU - long into earnings,"Strong earnings record of late. Discounting future cash flow at only 4.26% and showing real strong valuation - at least a 20% upside with really conservative figures. 

They have zero debt and more than enough money to buy the next cool thing if they ever fall out of favor with basic bitches and their spin class.  ",2018-03-26 14:31:53,['LULU']
0,"Long $WEN, DD inside. Shit is hard AF bois!",,2018-03-29 14:30:00,['WEN']
0,Long $LFIN - DD Inside,[removed],2018-04-05 17:05:11,['LFIN']
0,Long $GOOLAG DD INSIDE,[removed],2018-04-10 08:02:22,['GOOLAG']
0,Long $Briefcases,,2018-04-10 17:41:04,['B']
0,"Long AeroVironment, or buy the stock, idgaf! I'm super cereal guys","Been following $AVAV since the high $30s, they've been building small drones primarily for the army. Now they're expanding their independent consumer business and building bigger drones for the army.
http://www.avinc.com/resources/press_room/united_states_army_awards_12_million_contract_for_aerovironment_wasp_ae_sma

On top of that they're killing it in the electric car charging industry, which is literally about to bust into the spotlight like Mandingo at a Miami spring break beach party.
http://www.avinc.com/resources/press-releases/view/aerovironment_awarded_patent_for_core_battery_charging_technology

TLDR; The boost they got post-earnings and off that Stifel upgrade is just the beginning, they'll be at $100 by this time next year for sure.",2018-04-11 13:41:15,['AVAV']
0,Long $KO,,2018-04-11 18:26:00,['KO']
0,Kraft Heinz is next new innovator! Long $KHC,,2018-04-12 18:56:16,['KHC']
0,Long $BANANA,,2018-04-14 11:45:58,['BANANA']
0,"Long $PLUG , proprietary DD inside.",[deleted],2018-04-21 12:19:23,['PLUG']
0,Long $TRUMP,,2018-04-25 15:36:21,['TRUMP']
0,Long $SNAP and $FCAU DD inside,,2018-04-25 19:22:45,['FCAU']
0,Long $LQ. DD in link.,"http://www.sohnconference.org/wp-content/uploads/2018/04/AWalker_CorePoint-Sohn-Pres-vFinal.pdf

The deal closes this quarter. June 15 calls still decently cheap.

Edit: this idea pitch won the contest at Sohn",2018-04-25 21:35:50,['LQ']
0,Long $EA. DD inside,,2018-04-29 21:00:19,['EA']
0,Long $OPTT,[removed],2018-04-30 15:42:21,['OPTT']
0,"Long $WKUK, DD inside",,2018-04-30 18:09:14,['WKUK']
0,"Long $RBR, $AOBC, thanks David Hogg!",,2018-05-01 13:40:45,"['RBR', 'AOBC']"
0,Long $WB for 5/9 Earnings,"With how $BABA beat earnings expectations and $FB beat expectations, $WB should also beat expectations as its a Chinese socail media company. 

No FDs for me, but I am pretty sure it will be in the $110-115 price range; there seems to be a good amount of buy pressure keeping the stock above $114. 

**[Position](https://imgur.com/a/DG1oJ24)**



",2018-05-04 11:09:45,['WB']
0,Long $TERP and other solar energy stocks,,2018-05-07 19:56:11,['TERP']
0,Long $NYSE they know what the ladies like,,2018-05-08 21:55:09,['NYSE']
0,"Just went long on $SBUX and it‚Äôs moving like a snail. If it closes above $60 on Friday, I‚Äôm getting Daddy Schultz‚Äôs face tattooed on my ass",,2018-05-09 12:16:31,['SBUX']
0,"Cup and handle, long $KMI",,2018-05-10 10:55:46,['KMI']
0,Long $FLNT Buy @ $2.1,"This one is all you Robinhood users with &lt;$100 in your account. Fluent Inc. is a marketing consultancy company in its infancy. Last quarter reports were alright, but market reacted unfavorably and the stock plummeted 20%. 
Priced at $2.1 and at its 52 week low, its a great opportunity to get in. The company team is good and fundamentals are sounds considering its a fledgling company.

My assumption is a 50% rebound in the next 4-6 months.

Risk assessment- Moderate Risk : High Reward",2018-05-10 14:40:44,['FLNT']
0,Long $INTU,"Intuit Inc. is a company that owns Turbotax, quickbooks and mint. It has ripped this year. Bought it around $160 in Jan, now its $194. 

Earning coming out on May 22nd. IMO it has a huge market share and its going to continue to climb.

OTM Jun18 220 calls look cheap, if you want yolo.

Risk assessment- Low Risk : Moderate Reward.",2018-05-10 15:14:43,['INTU']
0,Shit $KR DD,"Kroger is at a buy price right now. It peaks around thirty and bottoms around 24. It's volatile as fuck when news happens because people overreact but its not going anywhere and its dividends are dank. If you're looking for a long term hold, KR is a solid option. It SEEMS to be going up but it does frequently dip after it starts going back up. 24 FD puts next week with 26 calls next month could be a good yolo (less risky than most yolos). If you want to long this, look to 30 as a price target and give it 6 months or 2 dividends. Get free money while you wait for the turn around.",2018-05-11 17:17:02,['KR']
0,$HEAR has been killing it. Long Fortnite and buy headsets if you like making money.,"Or don‚Äôt, and go broke",2018-05-12 01:14:35,['HEAR']
0,Long $TED DD Inside,,2018-05-15 01:09:28,['TED']
0,Long $ROOF DD inside,,2018-05-15 02:06:32,['ROOF']
0,$MU profit taking tomorrow imminent. Sell your FD calls if you got them; use the profit to buy FD puts. Long term bullish - buy July 20th calls (55 &amp; 60) on any drop this week.,"Also buy $JD July 20th $40 calls. 

Godspeed boys. ",2018-05-21 20:38:27,['JD']
0,summer biotech play for after MU moons - $SGMO long DD,[removed],2018-05-21 22:23:40,['SGMO']
0,Long $QQQ!!,,2018-05-22 13:18:51,['QQQ']
0,Long $SPOT and their unbelievably astute playlist suggestions,,2018-05-24 13:29:44,['SPOT']
0,$WMT may have put in a bottom yesterday.,It is sitting on long term support line here.  May be good for a quick trade. I bought some July $85 calls hoping it catches a bid and that sellers are exhausted.  GL.  ,2018-05-25 10:03:02,['WMT']
0,Michael burry was right. long $NESN,,2018-05-25 13:10:23,['NESN']
0,"Long $DOG, DD inside",,2018-05-28 13:40:44,['DOG']
0,"Long $CRISPR, DD inside","A cure for allergies. Scientists have already use...

https://www.reddit.com/r/AskReddit/comments/8n6rfg/what_big_thing_is_one_the_verge_of_happening/dzticrv",2018-05-30 12:52:10,['CRISPR']
0,Long on Salesforce $CRM,"1. Great Q1 results. 

2. Noticeable increase in GAAP- more than 6% y/y

3. So far, seems on point to reach guidance for this year

4. Almost all analysts have it on Buy rating (40 of 45)

5. Consensus price target $140 (currently trading at $130). I say it will go up 10% by next er.

6. [TA- broke resistance recently while avoiding M-tops. Bullish signal.](https://imgur.com/a/1VKggoK)",2018-06-01 12:46:37,['CRM']
0,"Long $LUV, they want to show us what FDs can do!",,2018-06-02 17:10:13,['LUV']
0,Another one bites the dust - Long $ATNM,[removed],2018-06-04 11:27:10,['ATNM']
0,"Bayer acquiring monsanto, dropping name. Long $MON",,2018-06-04 16:21:32,['MON']
0,"$PTLA CEO Bill Lis retires, Long Portola",,2018-06-04 17:47:53,['PTLA']
0,Europeans are actually retarded,"Recently moved back to  Italy after living in the US for 12years. News is all about Trump and what he said on twitter even over here. Its crazy how much better the US economy is and how delusional Europeans are to think they can challenge the tariffs. People on worldnews actually think Europe can cut the US out of world trade. During a fucking BULL MARKET... Food and Oil prices are ridiculously high over here. Milk is like $10 a gallon folks, that shits cheaper than water in the US. Unemployment is higher than the US peak during the recession. Immigrates are not an issue one day, the next they are; everyone is to much of a pussy to take a fucking stance one way or another.... God forbid you offend somebody by taking a stance on anything other than being against a mean tweet by Trump. 

Its absolutely insane. Unemployment is actually INCREASING here. Greece is like 20&amp;#37; or something. France and Spain are like 10&amp;#37;. Major European economies and nobody works. In closing, pizza is pretty good... Long $BABA and $PLNT; US and China are the future. ",2018-06-05 01:27:50,['PLNT']
0,"Long $TWTR, $ITEQ",,2018-06-05 02:25:29,['ITEQ']
0,Check out this typo that Google corrected when I was checking up on AMD stock. Long $GOOGL,,2018-06-06 17:27:22,['GOOGL']
0,"Long $LVS, KJU cashing in his VIX tendies",,2018-06-11 10:15:18,['LVS']
0,If you needed any more to long $DPZ they are now an infrastructure company.,,2018-06-11 17:59:03,['DPZ']
0,long $NTDOY,smash 5 bout to be a banger,2018-06-12 16:30:51,['NTDOY']
0,Long $SHOP DD inside,"They helped ya boi launch [LookLit.com](https://LookLit.com)

Long papa ;(",2018-06-12 21:31:02,['SHOP']
0,"Someone, probably Netflix, is going to buy AMC Networks ($AMCX) and/or AMC Theaters ($AMC). Get your calls in now","The media vertical integration buyout game is fucking ON. The DOJ is fucking asleep at the wheel and conoanies are going to go into a buying frenzy before dems take back congress. The Disney/Fox merger is in the limelight now but don't miss out on this trade.

The rumors of Netflix getting into theaters with their IP has been around for a long time and I feel the time to strike is now. Also, AMCX has some great IP (Breaking Bad, Walking Dead) and interesting shows in the pipeline that will benefit Netflix, especially when Disney and other companies eventually start pulling their content off of Netflix. If (when) the Disney Fox buyout goes through, Disney's streaming service is going to be a **beast**. Netflix has to bulk up now ($AMCX) and diversify revenue sources ($AMC).  Netflix will be laughing all the way to the bank when Disney has to pay them to play Frozen 2 in theaters. 

I also see someone buying Roku, maybe Amazon, to control their content and severely disadvantage competitive content providers on the platform. Maybe even charging them to host their channels.",2018-06-13 08:50:34,"['AMCX', 'AMC']"
0,Long $MISH,,2018-06-13 19:49:30,['MISH']
0,Long $DQ,,2018-06-13 19:54:45,['DQ']
0,Long $ADBE,Monthly subscriptions are annoying as hell but they make money. ,2018-06-14 05:46:57,['ADBE']
0,"First ever options buy, also long $T while it's cheap.","Liquidated my $AMD a few days ago, signed up for Robinhood and used $AMD money to made my first options trade with AT&amp;T:

5x $33 6/22 calls, and 5x $34 8/19 calls.

Obviously not a lot, but gonna get my feet wet losing hundreds before I dive in head first and lose thousands.


$T at a discount now and will go back up in the next couple months since the Time Warner merger was approved. ",2018-06-14 10:53:34,['T']
0,$IQ DD Inside,"I saw a post somewhere asking for some actual iQIYI DD so I figured I would do some for myself as well to give myself some piece of mind on this new meme stock.

For all intents and purposes, we will use Netflix as a comparison, though as it stands, iQIYI has more revenue streams than Netflix does. Since IQ closed around $40 today, I went ahead and looked for when NFLX was around $40 and made a comparison between what IQ has for Q1 18' and NFLX Q3 13'.

(everything in thousands except price or if there is a unit)

(everything converted to USD)

||IQ (Q1 18')|NFLX (Q3 13')||
|:-|:-|:-|:-|
|Price|$19|$44||
|P/E Ratio|undefined|68.88||
|Total Revenue|$757,510 | $1,105,999 ||
|Net Income|$(61,617)|$31,822 ||
|Net Income/EPS|$(0.31)|$0.54||
|Total Assets|$3,561,079 |$4,901,325 ||
|Total Liabilities|$2,235,974 |$3,696,955 ||
|w/ Shareholder Def.|$3,561,309 |$4,901,325 ||
|Total Paid Subscribers|\&gt;50,000|31,092||
|Revenue Streaming|$325,374 |$884,134 ||
|Total Revenue|$757,811 |$1,105,999 ||

iQIYI has had some incredible growth YoY and even between quarters, there is an article here [talking about the user growth](https://www.fool.com/investing/2018/04/27/iqiyi-growth-accelerates-in-its-first-quarter-as-a.aspx). The analysts there suspect growth to slow down in the range of 42&amp;#37; to 48&amp;#37;. I went ahead and did a safe growth of 35&amp;#37;. This would be for Q1 19' and resulted in some new numbers:

|Total Revenue|1,022,638|
|:-|:-|
|Total Assets|4,807,456|
|Total Liabilities|3,018,564|
|  w/ Shareholder Def.|4,807,767|
|Total Revenue|1,023,044|

These numbers are essentially NFLX at $44 so from the book standpoint, it is pretty safe to say IQ is CAN BE valued around $44 if their growth holds up. IQ's current stock price almost assumes that growth has gone up 35&amp;#37; since March rather than a full year of growth.

Realistically, the stock should be priced around $30-35, but this is understandable as to why it is trading higher than where its American brother Netflix was at a similar growth period because of their new AI competition, board changes, and user growth. NFLX was at \~$63 a share when they had 50 million subscribers, IQ already has that many subscribers and its growing, and even more free users. They also make about the same amount off advertising with their free users which is great news and have other revenue streams and continue to make new partnerships and release news between earnings. Knowing where there are in comparison to Netflix as a baseline is great because I know that anything below $35 is an immediate buy for me.

Enjoy the numbers, correct me if I am wrong anywhere. I know my total revenue is different than what articles have posted for total revenue (e.g $777M) but I converted RMB to USD from their balance sheet. Currently long $IQ and looking to pick up more if it ever goes below $35 x (some genius IQ premium multiplier).

tl;dr: might go up, might go down",2018-06-15 18:11:55,['IQ']
0,Drowning in Northern Mexican debt. Long $OIL,,2018-06-17 19:42:27,['OIL']
0,John Oliver‚Äôs latest story is on China. Long $JD $IQ $SOGO $HUYA,,2018-06-18 07:24:12,"['SOGO', 'HUYA']"
0,Long ITM $LUBE calls and sell OTM calls on $WSBQ as a hedge for a 4.20 credit,,2018-06-19 10:38:49,"['LUBE', 'WSBQ']"
0,Long $MSFT and $BRK.B DD Inside,"http://www.businessinsider.com/video-of-bill-gates-and-warren-buffett-in-a-candy-shop-2018-6

Get those tendies! ",2018-06-20 07:42:20,"['MSFT', 'BRK']"
0,Long $INTC,,2018-06-21 10:08:47,['INTC']
0,Long $VVV it‚Äôll Ease the Pain,,2018-06-21 16:18:05,['VVV']
0,Long $TAP (Molson Coors Brewing),"Robinhood is a failure. Also miscategorized as ""Gold"" stocks are $DF (Dean Foods), $PGE (PG&amp;E), $PPC (Pilgrim's Pride), $GIL (Gildan), $IMOS (ChipMOS Technologies), $FDP (Fresh Del Monte), and $TAP.A

https://imgur.com/a/wYGeUzM

If you haven't tried Two Hats, buy a case and spend the weekend in your mom's basement. If you're already there, buy a case, and wallow in your sorrows. Long $TAP

Disclaimer: this shitpost does not constitute a recommendation to buy or sell any of the mentioned securities, nor options on those securities",2018-06-24 11:13:22,"['TAP', 'DF', 'PGE', 'PPC', 'GIL', 'IMOS', 'FDP']"
0,"Long $CRSP, Entering the third phase! DD in comments.",,2018-06-25 01:33:12,['CRSP']
0,Elon scrapped their automated production line and is manually building cars under tents in the parking lot. Long $TESLA,,2018-06-25 12:36:26,['TESLA']
0,$EVBG looks really good right now,"Lots of long term contracts, low sales/ev multiple compared to other small cap tech/IoT companies, strong growth, consistently beating/raising on earnings. I picked some up yesterday. Probably gonna buy some August calls expiring after earnings soon.",2018-06-26 08:03:43,['EVBG']
0,Long $BO $OB $S - Yahoo Finance DD,,2018-06-27 08:06:13,"['BO', 'OB', 'S']"
0,"Bloomingdales sells blood now, long $M",,2018-06-28 15:49:46,['M']
0,$UXIN Sideways Circle Jerk Thread,"Enough with the celebration and suicide threads.  How ‚Äòbout some good ole fashion circ jerkin‚Äô to celebrate a 1% movement. Keep this momentum up and we‚Äôll give Ally a run for their money. 

Remember, circle jerks aren‚Äôt gay so long as they go to the right and not the left.",2018-06-28 16:22:38,['UXIN']
0,Long $CCL,,2018-06-29 02:20:10,['CCL']
0,$WDC Divergence,"About a month ago I posted about some bullish MFI divergence in [$RCL](https://www.reddit.com/r/wallstreetbets/comments/8plywc/rcl_entry_point/) and later it spiked up 10% not too long after. I'm back again with another one! Western Digital is showing basically textbook bullish money flow divergence. I own Jan 19 $80 calls. Could be a good time to jump in some shorter term calls. Perhaps look at the August $77.50 or October $80 calls.

Here's the [chart](https://imgur.com/a/h0fOJhy)",2018-07-02 10:05:35,"['WDC', 'RCL']"
0,All in on $GLD,"Gold looking way oversold. Just bounced off 200sma on the weekly which previously led to a huge rally. But this time it‚Äôs the same exact price as the last time it bounced. So yeah, big support. Dollar also weakening from trade war. I would go into oil but it‚Äôs too late, it looks way too high. GLD is the best commodity to go long from my view.",2018-07-03 10:26:10,['GLD']
0,Long $ABB You Faggots,[removed],2018-07-03 13:38:31,['ABB']
0,Long $JohnSilvers . (DD INSIDE),,2018-07-03 21:04:52,['J']
0,$GD looking to breakout from downward wedge,"For any TA boios out there, check it out

I'm long 2 Jan 19 calls, in at $11.43 each (includes commission and fees)",2018-07-06 11:22:42,['GD']
0,Long $Rats Yummy,,2018-07-08 16:25:40,['R']
0,"Definition of Contrarian News: China tariffs US fiber optics b/c of ‚Äúanti-dumping‚Äù. This means our guys have selling metric shit-tons of product for them to do this, long $GLW (also don‚Äôt forget about India building network!)",,2018-07-10 10:37:55,['GLW']
0,Long $GALT.,[removed],2018-07-12 20:47:59,['GALT']
0,DD Long Lennox ($LII),"It‚Äôs pretty hot out. So I bought air conditioner. And with this ‚Äúglobal warming‚Äù bullshit it‚Äôs probably good idea to buy stock in AC companies. 

Since it will be hotter more people will get more AC units. 

Long $LII",2018-07-15 22:52:55,['LII']
0,Long $CHGG. [DD by Trump included.],,2018-07-16 06:30:07,['CHGG']
0,Long $GPS. DD inside.,Banana Republic is so hot right now. ,2018-07-16 21:19:49,['GPS']
0,Was Starting to Feel Shitty About My $PYPL 7/27 FD Calls Until,"...This EOD Breakout:\[Third Point Interest\]([ttps://twitter.com/DeItaOne/status/1020397751169888257](https://twitter.com/DeItaOne/status/1020397751169888257))

Other Headlines in the past 24hrs

\[Credit Suisse Group Upgrade to $100\]([https://www.mareainformativa.com/2018/07/20/paypal-pypl-given-new-100-00-price-target-at-credit-suisse-group.html](https://www.mareainformativa.com/2018/07/20/paypal-pypl-given-new-100-00-price-target-at-credit-suisse-group.html))

\[Fintech Upgraded to Attractive at Morgan Stanley\]([https://www.investopedia.com/news/fintech-upgraded-attractive-morgan-stanley/](https://www.investopedia.com/news/fintech-upgraded-attractive-morgan-stanley/))

Earnings are 7/25, along with $V. ",2018-07-20 16:22:59,"['PYPL', 'V']"
0,"IDGAF about Trump's yapping, currently long $14,000 worth of $SPX calls for next week. Gains train inbound, Choo Choo bish!!",,2018-07-20 16:38:51,['SPX']
0,Long $TIGER,It‚Äôs happening ,2018-07-22 12:02:04,['TIGER']
0,"Long $BJ, DD inside",( . Y . ),2018-07-22 16:11:08,['BJ']
0,Long $USO,,2018-07-22 23:25:34,['USO']
0,$AMZN is 0.94 correlated with $GOOG - today we are all long $GOOG #prayForGOOG,,2018-07-23 15:55:16,['GOOG']
0,Why YOU should long $HOG --DD inside,"1. It's good.

2. Eurocucks finna eat it up.

3. Trump is going to hand everyone a big check next April and cousin Cletus will finally be able to afford one.

4. Indian has like 12 dealerships total. 

5. India, unrelated to Indian, finna pop and $HOG will be there when it occurrs. Invest in $HOG and you can tell people that you play ""developing markets."" Sound smart at parties and gain the respect of your redneck in-laws.",2018-07-23 23:48:47,['HOG']
0,$XLC: or how info tech/telecomm became sexy again,"Alright boios, earlier this month State Street launched a new ETF, $XLC trading at around $51.57 right now. ""XLC is a capitalization-weighted, non-leveraged, passively managed equity ETF with the benchmark index of Communication Services Select Sector Index. The ETF's geographic objective is Global with a focus on Communications Sector, Broad/Multi Cap companies.""

For you poorfags who can't afford $GOOG or $FB, this bitch gives you a good amount of exposure to both. Top 10 holdings of the ETF are: FB (21%) GOOG+GOOGL (25% collectively) ATVI (4.5%) DIS (4.5%) VZ (4.5%) EA (4.5%) CMCSA (4.5%) T (4.29%) CHTR (4.095). They also have a stake in NFLX, (3.93%, which I like) and TWTR (2.78% which I don't like).

As I'm long AMZN and NFLX, I like the fact that I get exposure to FB and GOOG in a more affordable and more diversified fashion.  I also think having some of the traditional telecomm dividend cash cows in this shit is good.  Sure, T is tanking right now but they're dividend is solid and stuff to provide a little bit of stability.

TL;DR: This etf blends the sexiness of GOOG and FB with the Buffett-ness of T and VZ. 

",2018-07-25 15:46:33,['XLC']
0,Long $SOY,"Trump ain't building walls, but making sure his core voters stay afloat to root for him so he wins 2020. This was only the beginning. He gonna make China buy that bible-belt soy. Praise kek",2018-07-25 18:48:54,['SOY']
0,Good entry point for Ford ($F),"Down ~3.5% from shitting the bed on earnings yesterday. Likely stocks not options the way to go, seems more long term but how low is this going to go and how long do we expect them to keep sucking. ",2018-07-26 12:58:29,['F']
0,Luke from LinusTechTips gave a shout out to WSB. Long $RGB!,,2018-07-28 04:32:19,['RGB']
0,Wait for $VIX to spike and reverse b4 going long,Futile picking bottom today.  Mebbe tomorrow but more likely Weds once Fed is out IMO. ,2018-07-30 11:15:29,['VIX']
0,$PETS update,"\*Updated below post\*

Cat food and pet medicine stock. Thanks to a massive oversupply of liberal arts degrees,  careerism trends, and feminist propaganda, 1-800-PetMeds ($PETS) has  seen booming growth in sales over the past year. In North America, young  adults are 8 times as likely to own a pet than a child, and pets are  now twice as likely to be vaccinated as children.

The  $30.6 billion U.S. pet food market is expected to grow 5.4% a year over  the next five years, but more importantly, the proliferation of  internet pornography continues to drive down marriage rates, and by  implication, drive up pet ($PETS) ownership rates, especially among  women.

$PETS uses an online model similar  to Amazon to disrupt traditional brick-and-mortar retailers and uses an  omni-channel approach to support rapid growth. Revenues are growing 13%  yoy and growth continues to be supported by unusually high prices on  prescription products.

The rising  standards of living for humans will trickle down to pets, and humans  will continue to spend more on pet health compared to how much we spend  on our own health. Long $PETS

\*\*Update\*\*

/r/aww has 17.6 million normie subscribers that spend most of their discretionary minwage income on their $PETS

I work at a hedge fund and I'm pitching a proper analysis to management next Monday

Thanks for all the laughs WSB you autists are fam",2018-07-31 10:58:06,['PETS']
0,I belong here $FIT,,2018-08-02 10:07:44,['FIT']
0,Long $BMY : Anti-depression drug Abilify linked to repeated large purchases of FDs,,2018-08-03 22:25:20,['BMY']
0,Long Lumentum $LITE and Oclaro $OCLR DD,[removed],2018-08-03 23:00:23,"['LITE', 'OCLR']"
0,Long live $ETSY calls,,2018-08-06 18:29:05,['ETSY']
0,Went long on $MSTX,,2018-08-08 01:56:12,['MSTX']
0,"Get in on the $YEXT big thing - Earnings play, actual DD","This isn't a Seeking Alpha article so I'm gonna try to keep it short-ish Plus some of you would read a TL:DR on a tweet if it was a thing.  

Yext created a whole new market segment called DKM-digital knowledge management. They are a ten year old company which has been public for about a year. Going public allowed them access to capital which let them expand and win many partnerships this year including Yelp, TripAdvisor,Google and Amazon.  It's a simple product. On the surface they allow merchants and businesses to update the information that appears on search engines and review pages.  Under the hood it's a beautiful AI play with rich and complex ramifications.  The digital Knowledge Assistant interacts with companies and let's them know when and how to change their info. For instance if people are searching How many calories in a big Mac on their alexa, the KA will prompt the neighborhood Burger Restaurant to add the info to their website along with their hours of business and whatever else info is pertinent.  

-Management is stellar. Highly ranked on Glassdoor, recently named best place to work by Fortune. Keeps winning partnerships. Last big pop was a big win with Alexa 

-Expected revenue this quarter is 54 million ish. However, due to new features and partnerships I think this is a very conservative estimate.  Good chance of a big beat.  

-Last earnings call they mentioned a line about being worried about capital expenditures due to their spending on annual conference. Now they just announced David friggin Blaine will be entertaining them. Just an aside but I think this speaks as to just how confidant they are going into this report.  

-Company is currently cash flow positive, many catalysts this spring/summer, history of big beats.  

I bought calls and stock.

Edit: Earnings isn't till first week of Sept. Stock is currently range bound by about 5%. Possible to wait for a sale before buying. If you're a masochist and like being glued to your computer can wait till last week and write calls to capture theta/iv

Edit 2: Sorry they just announced Aug 30",2018-08-11 18:23:42,['YEXT']
0,DD on a yolo $OMI,There's STRONG speculation that Amazon will be partnering with Owens and Minor for their health care expansion. May or may not know someone who works there... Problem is.. No clue when that would be announced if they beat out out Cardinal Health for the position . I think I might do a long term call since $OMI is at all time lows ,2018-08-12 14:29:37,['OMI']
0,$EBIX buy it and thank me later,Strong growth story. Do your own DD but I buy to add to my long term holdings on every pullback. This is over 85 end of year easily.,2018-08-13 15:40:54,['EBIX']
0,Buy calls for the god of thunder,"Ok I've had my eye on one company for a long time it's finally getting in my buy zone. $THO Thor Industries under 100$ is such a steal. It's a YOLO worthy option if you can catch this on its way back up, calls will be insanely profitable. 

Look at the balance sheet, look at the PE, look at the chart, do quant analysis, even ask wizdaddy I don't give a shit. They're all pointing up. That's your DD now go.",2018-08-13 16:47:01,['THO']
0,Long $SAUDI üòÇüòÇüòÇ they got this smart prince,,2018-08-14 08:44:30,['SAUDI']
0,"L Brands $LB (Victoria's Secret) - The Real ""DD""","Victoria's Secret parent company L Brands $LB shares are down 48% year-to-date and 67% from all-time-highs. The company reports earnings this Wednesday after market close, and is primed for a pop from the low following strong retail sector numbers earlier this week. 

L Brands has moved sharply downwards over the past two years as ""real beauty"" trends have pushed both retail competitors and institutional investors away from 'idealized' models and 'male-focused' lingerie products. This trend can only move so far however, and while larger sizes certainly exist, investors seem to have forgotten that Vic Secret holds a dominant brand and moat-protected competitive positioning in small-sized products aimed at younger women. The VS Fashion show is unrivaled among corporate names in viewership, and the list of names employed as Angels total a combined 100m followers on instagram. Additionally, overt feminist trends have stalled and begun to reverse in the Trump era.  

The stock currently trades at a tiny 6x P/E ratio, a number usually reserved for dead and dying companies. $LB however has posted 8% revenue growth its last quarterly, and has recently expanded into China with a huge flagship store in Shanghai, targeting overseas demand for American brand name products. 

For additional DDs, please see the attached photo. Long $LB &amp; 1 month calls through earnings week. ",2018-08-20 11:48:45,['LB']
0,Long $CANCER,,2018-08-22 14:50:05,['CANCER']
0,"Lets talk about $DKS, I feel its a strong buy.","Guys I think this is a real strong buy, first of all after the past three earnings reports theyve gained some good jumps. At the same time retail is booming, and Sportsmans warehouse which is a smaller shittier version of Dicks has enlarged 8% after earnings. My only concern is that there has been too much of a running tease up to earnings, as Dicks has never lasted this long in the green before. Maybe theyre past their breaking point of $30, or maybe theyre ready to come crashing down if anything goes sideways after earnings. But they are a real strong company so Im stroking a long Dicks position.",2018-08-23 13:42:27,['DKS']
0,Long Hershey Co ($HSY). Selling $87k of $BRK.B to buy in,[removed],2018-08-23 21:26:08,['HSY']
0,"Long $DG, presidential store of choice.",,2018-08-23 23:11:47,['DG']
0,Go long $SUBX. It‚Äôs that time of year.,,2018-08-24 09:31:43,['SUBX']
0,Long $DBX. Down 5% because of lockup expiration,"Lots of impatient insiders sold today at the very first chance dropping the stock 5%. Entirely undervalued, going long here",2018-08-24 10:22:23,['DBX']
0,$TTPH - FDA Approval of antibiotic,"So the other week I posted this long ass DD:

https://www.reddit.com/r/wallstreetbets/comments/96m8y0/random_biotech_dd_ttph/

And some of you idiots bought.  Congrats.  FDA approval, up 17% after hours, probably going to continue to trail up to $4.  $3.80 is my current price target as I am holding 5,000 shares at $2.87 average after seeing that nice dip under $3 I more than doubled my holding.


Next we will be waiting on $ADMP, which I also wrote up and have been slowly building position on.  Currently average is $2.78, that drop to $2.25 really helped me add my position.",2018-08-27 20:04:43,"['TTPH', 'ADMP']"
0,Long $DVL,,2018-08-28 12:28:58,['DVL']
0,Long $ATVI,,2018-08-28 18:25:41,['ATVI']
0,Long $WEED,,2018-08-28 23:20:41,['WEED']
0,PSA: it's flu-shot time: will make autists stronger this Fall,"You are already autistic so think of this as a booster shot to increase your trading prowess for the upcoming volatility, due to the mid-term elections.

Get the shots for low-cost at $CVS.   Long $CVS of course.   My CVS target is $80, as long as their merger with Aetna does not get cancelled. 
  
https://www.cvs.com/immunizations/flu
  
DISCLAIMER: this post is for entertainment purposes only and does not constitute medical or training advice.  Autists are supposed to do their own due-due-diligence.
 ",2018-08-29 22:06:51,['CVS']
0,1st time I've heard of Costco cancelling merch return abusers - Long $COST,,2018-08-31 00:53:38,['COST']
0,Long $MELANIA,,2018-09-01 08:53:00,['MELANIA']
0,Long $JAGX,,2018-09-02 17:19:47,['JAGX']
0,Long $DNKN,Three Dunkin Donuts locations opened up within 1 mile of each other where I live. Also fuck Starbucks. ,2018-09-03 18:30:31,['DNKN']
0,Long $CRON,,2018-09-04 09:23:45,['CRON']
0,Long $NKE the protests are full autism like we have not seen before. (Shitpost),,2018-09-04 21:47:59,['NKE']
0,Tendie Thursday confirmed (long $TSN),,2018-09-06 00:35:47,['TSN']
0,Long $FIZZ,,2018-09-06 04:35:52,['FIZZ']
0,Long $DDT,,2018-09-06 18:22:14,['DDT']
0,Long $WBA,,2018-09-06 23:16:42,['WBA']
0,Long $LAKE (DD inside),,2018-09-09 03:40:54,['LAKE']
0,"Long $ADDYY, DD inside",,2018-09-09 18:25:07,['ADDYY']
0,Long $BHF,"Interest rates are on the rise and you need to diversify into a company that might benefit in that scenario. This stock has a lower PE than MU and a slightly less shitty outlook.

 

|Forward P/E|4.29|
|:-|:-|
|Price-to-Book|0.36|
|Market Cap|4.8B|
|Enterprise Value:|6.19B|

[Source](https://www.gurufocus.com/stock/bhf)

&amp;#x200B;

Recent separation from MetLife has created increases operating and hedging expenses but a lot of that should go down over the next 6-18 months. Basically just costs a lot of money to recreate all the operating and hedging stuff under a new company. The company is new but the business is old and undervalued by any and every metric. It's not a sure thing they turn it around this quarter and long-term growth is doubtful but the assets they hold are currently worth 25% more than the current stock price so there is limited downside risk.

&amp;#x200B;

I think the stock could go up a lot or down a little. I own shares that I bought @$41. It's @ \~$40.20 right now. I'm hoping for a nice 10-30% return over the next year.",2018-09-10 11:47:08,['BHF']
0,Long $PVTL,,2018-09-10 20:01:39,['PVTL']
0,Long $HD,,2018-09-10 21:25:07,['HD']
0,$SAM The newest addition to the basic portfolio,"I went to a party and 7 out of 11 girls were drinking Truly. Two were drinking wine but loved Trulys, and the last two didn't know what they were. Basic girls love hard sparkling water.

Long $SAM - owner of the Truly spiked sparkling water brand. 

Hard sparkling water is going to take market share from light beer, rose, shandys, and ciders. I saw a girl make Truly and vodka drinks to get a head start.

$SAM sits at a $5bn market cap with the underperforming Sam Adams brand, but has the number 2 brand in the fastest growing segment in alcohol.",2018-09-11 12:18:10,['SAM']
0,"$HLT, $MAR, $NWL","Long hotels because people gotta have a roof over their head after the ‚Äòcain. Call it a vacation.

Long $NWL because they own Coleman and people who buy MU $90c‚Äôs can‚Äôt get a room and live in tents. Call it a camping trip.",2018-09-12 00:34:53,"['HLT', 'MAR', 'NWL']"
0,Long $NIKE DD inside.,Daddy cook is wearing Nikes at the release event.,2018-09-12 13:06:15,['NIKE']
0,"Turkcell: Get Paid to Fight Digital Imperialism, Play all EM Telecom with one stonk","Kaan Terzioglu is a badass and you want to invest in his company.

Turkcell is soaring today because the Turkish interest rate hike but also because of the statements yesterday from the CEO that they are working with Huawei to expand the Turkcell franchise empire which already is in Ukraine, Belarus, Cyprus to ALL emerging markets.

Turkcell will help emerging markets either develop their own app suites to compete with western ones or will let them use Turkcell apps with their own skins. 

Telecoms have long been the stablest way to play EM and I‚Äôve been pumping $TKC here for a couple weeks now. Wanted to post this link yesterday but I was banned for 24 hrs.

https://www.developingtelecoms.com/Categories/tech/apps-content-ott/8015-rebelling-against-digital-imperialism-interview-with-kaan-terzioglu-turkcell.html

The beauty of Turkcell is that they are interwoven with the Turkish government without being owned/dependent on them. The major shareholder is Telia whose major shareholder is the Swedish sovereign wealth fund. 

And a ranking executive of Turkcell just took a major job in Erdogan‚Äôs communications department. They are also a key investor in Erdogan‚Äôs Turkish car initiative. 

",2018-09-13 12:57:47,['TKC']
0,Elon buying his new car after getting tired of waiting on his model 3. Long $NIO,,2018-09-13 20:00:52,['NIO']
0,Long $HMNY DD inside üòÇ,,2018-09-13 21:48:39,['HMNY']
0,"$IMDZ - Immune Design, done for now Im drunk","#**IMDZ ‚Äì Immune Design Corp**


#**Overview:**

Immune Design is a clinical-stage immunotherapy company focused on developing treatments to enable the body‚Äôs own immune system to fight diseases.  Their focus lies on the oncology sector, having engineered technologies to activate the immune system‚Äôs natural ability to create tumor-specific cytotoxic T Cells to fight cancer.  Their belief is that their two main drug candidates will address what other therapies are currently lacking while having the potential to treat a broad patient population through either individual therapies or in conjunction with other mechanisms of action.  Although their main focus is the immuno-oncology, they believe that their candidates also have potential to serve in therapeutic realms such as infectious and allergic diseases as they have a few different collaboration and partnerships underway leveraging their GLAAS platforms.  

Immune Design‚Äôs management team, board of directors, and scientific advisory board boast a diverse group of individuals who don‚Äôt lack experience in the industry.  The CEO, Carlos Paya, has served as Vice President at Eli Lilly, President of Elan Corporation, and was also a professor of Medicine, Immunology, and Pathology at the Mayo Clinic in Rochester, Minnesota.  The company also has an extensive list of Doctors and PhD researchers backing the company‚Äôs advisory board and management team.
  

#**Pipeline:**

The company currently has 6 different products in their pipeline ranging from Preclinical to Phase II.  Still in the early stages of development, the company is actively seeking growth and partnerships to solidify their financial and developmental future.  Each of their GLAAS products, 3 of them, have partnerships lined up for the development and licensing of the candidates.  These partnerships include Sanofi, MedImmune, and Sanofi Pasteur.   To match their product collaborations, they are also working in conjunction with Merck and Genetech in clinical collaborations to evaluate the safety and efficacy of their immuno-oncology products. 
Their immuno-oncology pipeline also has 3 candidates targeting different forms of cancer.  Their entire pipeline is as follows:

 

#**Specific Drug:**

While the company has several different products filling their pipeline, we are concerned with CMB305.  Immune Design has entered into a clinical trial collaboration with Genetech, a member of Roche, to better evaluate the safety and efficacy of CMB305 cancer immunotherapy when combined with the investigational cancer immunotherapy atezolizumab in patients with soft tissue sarcoma.  

CMB305 is a prime-boost product designed to target tumors that express the NY-ESO-1 tumor antigen, specifically soft tissue sarcoma.  NY-ES0-1 is expressed in a large number of solid and liquid state tumors in varying degrees.  CMB305 is comprised of two parts, a ‚Äúprime‚Äù and a ‚Äúboost‚Äù, which are designed to work synergistically to induce anti-tumor cytotoxic T lymphocyte (CTL) response targeting the NY-ES0-1-expressing tumors.  It is also hypothesized that CMB305 will also generate memory CTLs, providing for long-term immune response systems while enhancing other immune anti-tumor mechanisms along the way.  

Currently, CMB305 is in different stages of clinical development, which include monotherapy Phase I as well as a fully-enrolled Phase II trial comprised of individuals with two subtypes of soft tissue sarcoma (synovial sarcoma or myxoid/round-cell liposarcoma).  This combination study is utilizing either CMB305 with Genetech‚Äôs cancer immunotherapy TECENTRIQ, or atezolizumab alone. 

Last year, the company reported positive clinical and biomarker data for CMB305 as a monotherapy.  In 25 soft tissue sarcoma (STS) patients with recurrent disease treated with CMB305, median overall survival (mOS) had still not yet been reached, with an overall survival rate at 12 and 18 months of 83% and 76%, respectively. These data compare favorably to mOS for approved second line and later sarcoma agents, which is only 12.4-13.5 months, as well as a published mOS of 11.7 months for synovial sarcoma patients specifically; the largest patient population enrolled in this trial. A disease control rate of 64% was observed, including durable tumor growth arrest in patients who had evidence of disease progression at study entry. Also, CMB305 was well tolerated, and generated a strong and broad anti-NY-ESO-1 immune response in &gt;50% of the patients, including evidence of antigen spreading ‚Äì the induction of an immune response against other tumor antigens not targeted by CMB305. In addition, the presented data showing a statistically-significant association of an induced response and clinical benefit in a pooled set of patients treated with CMB305 or LV305. The immune biomarkers studied, including novel bio-markers derived from public TCRS may guide regulatory strategy via the selection of patients more likely to have survival benefit on CMB305 therapy benchmarks. 

Immune Design has received Orphan Drug Designation in soft tissue sarcoma for both components of CMB305 in the EU and US, and depending upon further trial results soft tissue sarcoma will be the first indication in which CMB305 will be filed for regulatory approval.  There is a significant unmet need in this market, and the company holds the stance that the potential benefit of CMB305 to patients will be higher safety for patients and improved survival rates. 


#**Current and Forecasted Market:**

Synovial sarcoma is a cancer in the joints with a five-year and ten-year survival for people with Grade 3 tumors or metastatic disease of less than 25% and 15%, respectively, and Myxoid round cell liposarcoma is a malignant tumor that most often occurs in the deep-seated soft tissues of the extremities. Currently marketed treatments have high toxicity, with up to 37% of patients experiencing Grade 3/4 Adverse Events. 
Soft tissue sarcoma is rapidly growing, expected to reach a global CAGR of over 8% over the next 6 years.  With over 50 different types of soft tissue sarcoma, it is a rare and diverse group of cancers that can develop from nearly any tissue.  There are approximately 13,000 individuals who suffer from soft tissue sarcoma each year, and with a high incidence rate and increased awareness about the condition, the market is expected to continue to expand.  
The current soft tissue sarcoma market size is valued around $700 million as of 2017, and with an expected CAGR of more than 8%, In 2017, 12,715 new diagnosis and 5,070 deaths due to STS were reported in the U.S. Bone sarcomas accounted for 3,373 new cases and 1,649 deaths in 2017. The lifetime risk of developing a sarcoma is 0.4%. Approximately 45.0% of bone sarcomas and 21.0% of STS are diagnosed in people in the age group of 0-35 years.  Currently, chemotherapy and targeted therapy are the only approved treatments for sarcoma.  Several immuno-oncology agents are also under investigation, with Immune Design leading the forefront to fill this unmet market need. 


#**Competition:**

The largest market competition are companies such as GlaxoSmithKline, Eli Lilly, Pfizer, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson &amp; Johnson, Teva Pharmaceutical Industries, and Celgene and others.  However, not all of these companies are focusing on developments in immuno-oncology and developing long term body resistance to tumors.   There is a large market for immuno-oncology that is unmet and waiting to be filled.  Novartis holds roughly 30% of the market share for sarcoma treatment, which Immune Design seeks to start to take if the product becomes approved.  


Financials:

MDZ reported loss of 29 cents per share in second-quarter 2018, narrower than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 54 cents.

Immune Design‚Äôs shares have lost 8.9% year to date compared with the industry‚Äôs decline of 1.2%.  However their revenues are up this quarter YOY to $0.76 million mainly due to the collaboration with Sanofi for G103 and product sales to collaboration partners.  R&amp;D expenses are increasing as they are moving along their extensive pipeline through the clinical phases.   

Biggest note on their finances, Immune Design expects cash on hand to be enough to fund operations through the second half of 2020.  Due to their strategic partnerships and financing, the company is able to limit diluting investors or taking on greater debt.  The company has enough cash and cash equivalents, $73 million, to finance all operations for more than a year, which is a very rare occurrence in these small cap biotech companies. 


#**Review:**

My sort of concerns, the low rate of success that oncology drug candidates have with the FDA.  Cancer is a tough market.  Data shows that cancer drugs have the lowest success rate of making it from Phase I to FDA approval, a mere 3.4%.  Although, cancer trials that used biomarkers had higher success rates, though, and the overall oncology drug approval rate for 2015 was 8.3%, which was due to the booming immuno-oncology field.  So, although oncology drugs lag, immuno-oncology pulls does not.  The past few years, especially under the Trump administration, drug approval rates have been higher than ever in recent history.  

For this product, Phase II studies patients and provides researchers with additional safety data to refine research questions and develop further methodologies to study the candidate and efficacy.  They utilize this data to formulate Phase III protocols.  Will not really reveal any benefits of the drug or therapeutic effects, rather simply show the safety of the product with some minor data.

As stated earlier, the company believes that CMB305 to patients will be higher safety for patients and improved survival rates.  Along with Orphan Designation and the need to get effective drugs approved in the Oncology market, I believe the FDA will try to push a product such as this through. I have no fear of dilution due to the cash on hand to hold them for another two years. 

Looking at their chart, the stock price has held a $3.30 support zone for the past year, consistently bouncing off of these low levels producing 10% plus gains and even going as far up as $5.00 just a few months ago.  The volatility of this stock is fairly high, and I would personally use this to my advantage.  They diluted with a $80 million offering in October 2017 causing a massive drop in share price.  I doubt the company will seek to ruin their shareholder base further any time soon.  I feel a purchase at under $3.40 is a great move and holding for $4.00 minimum.  


#**TLDR**:

Shit looks like a solid buy at this cheap support level.  They are showing safety in their studies or hinting at it, Phase II is all about safety, and with the Orphan Drug designation they have potential to meet a dire need.  Plenty of cash on hand, already screwed their investors with a dilution a year ago, dont have to worry about a dilution for another year or so as they have cash on hand to operate for two years.  I can see a 20-30% increase in the next month or two going from $3.30 to $4.00 as my minimum price target. 
",2018-09-15 02:57:55,['IMDZ']
0,$INSG,"Anyone have have thoughts on this company.
They have products for the 5G revolution bringing 5G into consumer homes and a Saas product with high margins.
They have contracts with some large carriers like Verizon and AT&amp;T.
There R1000 model is supporting Verizons 5G home, world's first 5G broadband internet service.
I think this could be big long term. 5G broadband promises speeds of 300-1gb internet, and pricing seems much lower.
For instance Verizon is launching the service at $50/month for current customers and $70/month for new users.
I currently pay AT&amp;T $50 for 50mbs internet and it's garbage.
Not sure about options but I'm buying shares
",2018-09-16 13:14:07,['INSG']
0,$RSGE play for October,"I‚Äôve been holding a fairly large position share wise of this since June, constantly buying with what‚Äôs left over after options trading and such. They have $60 million in reservations for their new solar shingle that has a better warranty than Tesla and is 15% cheaper to install than conventional solar panels. They‚Äôve taken a beating this year over solar cell tariffs but in October they expect UL certification to begin the distribution of the new Dow developed tiles to eagerly awaiting dealers. They‚Äôve accelerated training, and invested in manufacturing/logistics to keep up with demand. The California law requiring all new construction to have solar power will help this along further as this is mostly a west coast operating company. It‚Äôs cheap as shit and volume is steadily rising each week. It‚Äôll be easy money if you can stand to wait a couple months. I‚Äôve known about this since the earnings call in August but wanted to hear any thoughts from my fellow autists.",2018-09-18 13:11:19,['RSGE']
0,Long $TLRY now! We using Marijuana to sedate animals!,,2018-09-19 15:20:47,['TLRY']
0,FDs that will actually make you money! $BX,"Good evening all,

Now that we have gotten our weekly spectacle from $TLRY allow me to point you in the direction of a trade coming up.

$BX has their investor day this Friday (sep 21) , coinciding with some nice FDs.

The plan is the following: buy puts on Thursday in anticipation of the event Friday. Stock has run up on expectations that $BX will change to a C-Corp, like KKR which is up 30%+ since July.

Goldman did an analysis showing that this just isn‚Äôt likely due to the less meaningful benefit to the stock. They suggest you go long vol on the event, but with the stocks run up this week, I am thinking that I just want to be short.


I‚Äôve got 25 36.5 weekly puts and 10 more 36.5 expiring Friday the 28th. 

You can buy the weekly FDs for 10c. I‚Äôm looking to unload them for $1. 

Thanks for your attention and may the tendies be ever in your favor. ",2018-09-19 20:00:36,['BX']
0,$REV - Next Tilray - Count the tendies,"Alright I'll give the brief DD and credit @moxreports for this information. 

Full disclosure I have been long since revlon disclosed their last quarter earnings and myself (and big daddy ronald perelman the 85% shareholder who wants to take rev private) snapped up some shares @ 15 and now its sitting @ 25. Originally had shares and rolled over to contracts and now riding those out. 

&amp;#x200B;

Over 100% of the float is shorted (yes for u retards this is poissible. Perelman has been snapping up shares and he wants to take the company private. They have a backdoor provision in their contracts to transfer assets away from bondholders similar to Jcrew. He wants to do this while private so they face less scrutiny etc.. whatever yada yada. Right now out of 53.5MM shares effectively 2.5MM is the float sine perelman has 85%, indexes, and a few other activists investors are holding and have the intent to hold for quite a long time as you can see by the mittleman brothers 13F filings. This thing could overshoot HEAVY in the near term and it looks like perelman is going to have to announce private real soon. He has used these tactics many times before (buy when underlying is depressed following poor earnings - even though this is attributed to front end costs). He has paid anywhere between 50-100% premium when taking companies private.

Basically long revlon and count your fucking tendies. I'm sitting on Nov 25's right now (up 214% this is excluding my previous Sept 20's which I sold and profited from aswell as the shares). May roll if I see a longer time frame, but perelman doesn't want to see this stonk overshoot. ",2018-09-19 22:53:33,['REV']
0,$EVBG is a great buy right now.,"I've posted about $SSTI a lot in here. I think $EVBG is a great compliment to them, and right now their valuation looks a lot more appealing. I love $SSTI and I am holding a core position long term, but I've trimmed a lot between $55 and $60. They are pretty expensive now when comparing their ev/sales to other high growth software companies.

$EVBG, however, is much more attractive. I believe it has a lot of upside that we can see in the next few months. They have a lot of long term contracts which helps reduce long term risk. They have strong, accelerating revenue growth and they are being smart in their efforts to balance growth vs their path towards profitability. They are currently trading at around 12.5x ev/2018 sales. IMO they warrant at least 16x, implying an upside of \~28%, or \~$74 per share (trades around $58 now). 16x ev/2018 sales would be much more in line with what we see in other small cap/high growth tech companies.

Earnings report should be in early November. I am holding a medium ish sized position and will likely continue to add over the next month or so.",2018-09-20 09:58:09,['SSTI']
0,Long $GREC,,2018-09-22 22:53:31,['GREC']
0,Long $ACB,,2018-09-23 13:05:00,['ACB']
0,Long $SIX,,2018-09-24 15:26:28,['SIX']
0,"My take on $PLUG power, near and long term tendies, DD inside","**TLDR**: Buy $PLUG $3 11/16 calls for tendies as Plug Power will see the results of opening new factory, developing robots to take advantage of autonomous forklifts and delivery trucks, and developing new tech to double power storage. $AMZN, $NKE, and $WMT already use their equipment (and will purchase more) and $FDX has conducted 7500mi of deliveries in the Albany area using a Plug Power powered FedEx truck.

&amp;#x200B;

**DD**:

WSB listen up - Plug power is going to pop soon with a price target of $3.57, a 90% increase over its current price for the near term tendies. It will increase over the next quarter further as it completes its transition from research company to viable manufacturing company. I have 155 $3 11/16 calls for the near term tendies based around its 11/8 earning report, which I'll then turn over to 3/15 calls for the long term tendies where I expect it will jump yet further.

Walmart, Amazon, Nike, and FedEx have opened contracts with Plug Power for hydrogen powered forklifts and vehicles. Hydrogen power might seem lame but their niche is in industrial forklifts and local deliveries where time spent recharging is thousands of dollars a minute. Their CEO Andy Marsh has also been named to the U.S. Department of Energy Hydrogen and Fuel Cell Technical Advisory Committee, giving the business the political connections it needs to succeed. Jonathan Silver, a member of the board of directors, is also a former US Department of Energy official. They are also pursuing European expansion to become an international company, where the political connections will offer them an advantage over their competitor Bloom Energy.

All eight of the board members have purchased hundreds of thousands of shares in the company four times since the beginning of the year, most recently in late August, signalling that they see a positive future for the company as it has turned around from a research company to a viable industrial and manufacturing business. Institutional investors have increased their stakes by millions of shares - Odey Asset Management Group Ltd bough an additional 2,330,000 shares increasing their stake in the company to 4,910,000 shares. Ignore the misleading title of the article and read content for a breakdown of the institutional investor increases: ([https://www.fairfieldcurrent.com/2018/09/23/insider-selling-plug-power-inc-nasdaqplug-director-sells-31343-shares-of-stock.html](https://www.fairfieldcurrent.com/2018/09/23/insider-selling-plug-power-inc-nasdaqplug-director-sells-31343-shares-of-stock.html))

This is also different than a vehicle running on LPG or other alternative fuel. The hydrogen isn't burned in the traditional sense, but is instead run through a membrane that strips the electrons from hydrogen using a catalyst and generates electricity directly from the reaction - the hydrogen then bonds with available oxygen and generates water as a byproduct. The advantage of this type of system is the reduced refueling/recharging time compared to traditional electric forklifts that are used in warehouses, and the reduced emissions compared to traditionally powered forklifts. Their systems are retrofit-capable and can be fitted to currently owned electric forklifts, reducing the overhead of purchasing all-new equipment.

They have also in-sourced the production of the membrane electrode assemblies to further reduce costs ([https://www.gasworld.com/interview-with-plug-power-ceo/2015463.article](https://www.gasworld.com/interview-with-plug-power-ceo/2015463.article)) and opened a new almost 40k SQFT factory in Rochester New York ([https://dailygazette.com/article/2018/08/15/plug-power-adds-factory-in-clifton-park](https://dailygazette.com/article/2018/08/15/plug-power-adds-factory-in-clifton-park)). They used to purchase their membranes for their equipment from their competitor Bloom Energy, and now that they are producing their own membranes they have announced two new pieces of technology - a new membrane that doubles the energy output of its fuel cell system. They have also partnered with Rensselaer Polytechnic Institute and the US DOE to develop a robotic fueling station and reduces the time needed to refuel and allows the the usage of autonomous warehouse equipment powered by its system. ([https://fuelcellsworks.com/news/plug-power-rensselaer-polytechnic-institute-and-national-renewable-energy-laboratory-develop-robot](https://fuelcellsworks.com/news/plug-power-rensselaer-polytechnic-institute-and-national-renewable-energy-laboratory-develop-robot))

&amp;#x200B;",2018-09-25 12:38:29,['FDX']
0,Long $GRUB free tendies,,2018-09-25 18:08:33,['GRUB']
0,Long $FL,,2018-09-26 12:27:54,['FL']
0,"It's time to go full, buy ARG","New deal with IMF.

Sensible Central Bank policy.

Cheap AF in USDLR.

Bonds recovering, even long duration ones.

EEM index on the rise.

You are not fully autistic if you don't own one of these $GGAL $BFR $TGS $YPF",2018-09-27 08:34:21,"['GGAL', 'BFR', 'TGS', 'YPF']"
0,Coca-Cola stands for victims....Long $COKE,,2018-09-27 14:04:00,['COKE']
0,Autists still long $GERN,,2018-09-28 15:20:49,['GERN']
0,Long $HEXO - working with Wu-Tang (DD inside),,2018-09-30 09:33:16,['HEXO']
0,Chase Sapphire Reserve is the fucking GOAT: Long Live $JPM,[removed],2018-09-30 22:06:25,['JPM']
0,Long $TOY,,2018-10-02 18:15:26,['TOY']
0,Long $MAT,,2018-10-03 03:38:03,['MAT']
0,$ALKS - Alkermes DD,"#**$ALKS ‚Äì Alkermes**


**About:**

Alkermes is a global pharmaceutical company based out of Ireland. As a leader in innovative medicine addressing unmet needs in the market.  With a global reach and vast resources, this company is developing products to make a meaningful difference in the world and how patients are monitoring their diseases.  Uniquely positioned, Alkermes is an engine of innovative treatments for major clinical conditions specifically focused on central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.  

Alkermes has proven expertise reflected in a diversified commercial product portfolio, featuring ARISTADA and VIVITROL as well as having granted multiple different licenses to their proprietary technology in both the United States and European Union which expand the company‚Äôs portfolio.  This technology is paving the way towards improved treatments and discovering new, patentable medicines.  The company also boasts a pipeline of novel product candidates focused on CNS diseases in clinical development, keeping the patients needs at the forefront of their focus. Positioning their company with strategic partnerships, Alkermes has developed collaborations with some of the worlds largest pharmaceutical companies to help generate new and innovative medicines.   A partial list of Alkermes partnerships include Biogen, AstraZeneca, Janssen, Acorda, and Acceleron.  

Richard Pops, the Chairman and CEO of Alkermes, has been CEO of the company since 1991.  Since taking over the company, he has grown the company from a small private company of 25 employees to a powerhouse biopharmaceutical company with more than 2,000 employees.  Currently serving on the board of directors of Neurocrine Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization (BIO), the Pharmaceutical Research and Manufacturers of America, and the National Health Council.  Pops brings quite an impressive background to the table, with almost 30 years as CEO of his current company and aiding in improving several others, he displays a track record of success. 

The company also focuses on their responsibility in all aspects of the word.  Alkermes supports educational, healthcare-related, and public policy events through partnerships and donations which are aimed at central nervous system disorders such as depression and schizophrenia.  Contributing to individual education by providing educational grants, Alkermes focus lies on activities which improve patient care and public health in CNS disorders.  Committed to their patients and furthering the field of medicine, Alkermes remains a leader in treatments for CNS disorders.


**Pipeline:**

As previously mentioned, Alkermes has a robust pipeline of not only completed products and partnerships, they also have several drug candidates in various stages of clinical trials. 

Their fully approved drugs include:

*ARISTADA ‚Äì Long-acting, atypical antipsychotic

*VIVITROL ‚Äì Once-monthly medication to treat alcohol dependence and prevention of relapse to opioid dependence


Products in the US utilizing Alkermes technology:

*BYDUREON ‚Äì AstraZeneca product to treat type 2 diabetes

*RISPERDAL CONSTA ‚Äì Janssen product to treat schizophrenia and Bipolar I Disorder

*INVEGA SUSTENNA ‚Äì Janssen product to treat schizophrenia and schizoaffective disorders

*INVEGA TRINZA ‚Äì Janssen product to treat schizophrenia in patients already treated with SUSTENNA


Products in the EU that utilize Alkermes technology:

*BYDUREON

*FAMPYRA

*RISPERDAL CONSTA

*TREVICTA 

*XEPLION 


Their Research and Development side of the business has several late stage drug candidates in Phase III or have filed NDA, with one product in early stages at Phase I.  

*ALKS 5461 ‚Äì NDA Filed for Major Depressive Disorder

*ALKS 3831 ‚Äì Phase III for Schizophrenia

*BIIB098 (Formerly ALKS 8700) ‚Äì Phase III for Multiple Sclerosis

*ALKS 4230 ‚Äì Phase I in Immuno-oncology


Alkermes has two big FDA deadlines and events in the upcoming months which will be the focus of this write up.  The first is ALKS 5461 for the treatment of Major Depressive Disorder with the FDA advisory committee discussing the NDA application for the drug candidate on November 1st as well as a PDUFA date of January 31, 2019.  The second is ALKS 4230 for treatment of Solid Tumors, where they are reporting Phase I initial data in the second half of 2018.  I will be setting 2 dates for this write up to remind investors of the Advisory Meeting/data presentation sometime in the next 2 months, as well as the PDUFA date of January 31, 2019.  With multiple catalysts in the pipeline in the next 3 months, Alkermes is an exciting company to watch.


**Specific Drugs:**

**ALKS 5461**

AKLS 5461, buprenorphine/samidorphan, is a k-opioid receptor (KOR) antagonist which functions as an adjunct to antidepressant therapy in treatment-resistant depression (TRD).  The buprenorphine is a partial agonist of ¬µ-opioid receptors (MOR), antagonist of the KOR, as well as a slight antagonist of the Œ¥-opioid receptor (DOR), and a weak agonist of the nociception receptor (NOP).  Samidorphan on the other hand is a preferential antagonist of the MOR, allowing for the combination of the two to function as a stopper to KORs with negligible activation of MORs.  
Essentially this means that by activating the KOR, opioid peptides which are endogenous ligands of the KOR and function by inversing morphine-like, euphoric endorphins, create a sense of dysphoria and psychotomimetic effects, and are to produce changes in neuroplasticity evoked by chronic stress that has led to the development of depression and CNS disorders and drug addiction.  It is suggested in research that inhibiting the KOR abolishes antidepressant-like effects of buprenorphine, but the drug exhibits both antagonistic and agonist properties.  This has led to the concern that in theory, ALKS-5461 could be limited in the effectiveness of treatment of depression.  

Granted a Fast Track Designation in 2013, the drug has proceeded up to Phase III where thee different trials were initiated for the treatment of depression.  The first two trials failed in 2016, FORWARD-3 and FORWARD-4, however based on the third trial, FORWARD-5, the company submitted an NDA in 2017 for ALKS-5461.  Things started to look grim for the company moving forward, as the FDA served Alkermes a refuse-to-file letter saying that more data from well-controlled clinical trials must be presented before an application would be recognized.  However, just two weeks after serving the notice, the FDA rescinded their letter and accepted the NDA after productive interactions with Alkermes where the company clarified certain aspects of the NDA.  No further data was needed to rescind the letter and PDUFA date is scheduled by January 31, 2019.

The first two trials failed after the company reported higher placebo responses as the chief obstacle in their studies.  Not something a company would like to hear in relation to an antidepressant medication.  Causing the stock to plummet 44% in 2016, from nearly $80 to under $40, the company has been slowly recovering since.  ALKS-5461‚Äôs fate lies in the hands of FORWARD-5, without a clear success and perfect data, an FDA approval seems unlikely for this drug. 

FORWARD-5 focused on two doses of 1mg/1mg and 2mg/2mg of ALKS-5461 for adjunct treatment in patients with major depressive disorder (MDD).  Concurrently to taking ALKS-5461, the patients also remained on background antidepressant therapy.  With 407 patients enrolled, 63 received 1mg/1mg, 63 received 2mg/2mg, and 280 received the placebo.  The study was conducted in two stages: Stage 1 was 5 weeks, Stage 2 was 6 weeks. In Stage 1, the average change from baseline depression scores was calculated for weeks 3 through 5. For Stage 2, the average change was calculated for weeks 3 through 6. Depression scores were assessed using the 6-item Montgomery‚Äì√Ösberg Depression Rating Scale (MADRS-6) and MADRS-10, an assessment tool for depression.

In the study, ALKS-5461 2mg/2mg met the prespecified primary endpoint of significantly reducing depression scores compared to placebo, as measured by 6-item MADRS scores (p=0.018). ALKS-5461 2mg/2mg also demonstrated statistically significant reductions in 10-item MADRS scores compared to placebo (p=0.026). The 1mg/1mg dose of ALKS-5461 showed improvement in depressive symptoms in the study, but did not separate significantly from placebo.  2mg/2mg treatment did show a significant change, warranting its efficacy while also having no incidences of withdrawal or pattern of adverse effects suggesting abuse potential.  The clinical benefit of the compound maintained through 11-week study and the compound is relatively safe and tolerable.  Where FORWARD-3 and FORWARD-4 failed to meet their endpoints, FORWARD-5 succeed in meeting primary endpoint for the 2mg/2mg dose, showing great efficacy when compared to a placebo.   
November 1st, 2018, the FDA advisory committee is meeting to discuss ALKS-5471 in relation to the compound‚Äôs efficacy, safety and risk-benefit profile of the NDA for buprenorphine and samidorphan sublingual tablets for adjunctive treatment of major depressive disorder.  In recent history, the FDA has gone against the decision and vote of the advisory committee roughly 10% of the time over all, with 30% of the votes being against approving the drug and 70% of the votes being for approval.  

**ALKS-4230**

Currently in Phase I of development, Alkermes does a change of pace with this immuno-oncology drug for the treatment of solid tumors, making a shift away from their regular market in the CNS disease space.  This drug candidate is an engineered fusion protein comprised of permuted interleukin-2 (IL-2) and IL-2 Receptor (IL-2R) Œ± made specifically to only activate the intermediate-affinity IL-2R.  The intermediate-affinity IL-2R is expressed mainly on effector lymphocytes, which are essential in generating an antitumor immune response.  IL-2 is a cell signaling molecule which plays a role in controlling the life cycle of specialized T-cells.  ALKS-4230 selectively binds to intermediate-affinity IL-2R to both activate and increase in number the immune cells that work to battle cancer.  Their selectivity, however, means they don‚Äôt bind to the ‚Äúhigh-affinity IL-2 receptor,‚Äù so as not to trigger greater activity or proliferation in immune cells that could dampen an anti-tumor response Research has suggested that selective activation of the intermediate-affinity IL-2R by ALKS-4230 has the potential to provide enhanced tumor killing as well as improved tolerability. 
ALKS-4230 is currently in Phase I in patients with advanced solid tumors. Key study objectives are to determine a recommended phase 2 dose and characterize the safety profile, pharmacokinetics (PK), pharmacodynamics (PD) and evidence of antitumor activity. A dose-escalation phase in patients with refractory solid tumors (Part A) will be followed by expansion cohorts in defined populations (Part B). ALKS 4230 is administered as a 30-minute intravenous infusion once daily for five days each cycle. The dose will be escalated until reaching maximum tolerated dose or an Optimal Biologic Dose. The first two dose cohorts will use a 3+3 design. Subsequent cohorts in Part A will enroll a minimum of 6 subjects. In Part B up to 21 patients will be enrolled into each of four tumor-specific cohorts. Peripheral blood samples will be collected for PK, immunogenicity and PD assessments. The primary PD endpoint is change-from-baseline in CD8+ T, NK and T reg cell counts. Other PD measures include serum concentrations of multiple proinflammatory cytokines and immunohistochemical assessment of markers of immune activation in tumor tissue from selected patients. 

Animal trials conducted previously were positive and showed the anti-tumor activity of ALKS-4230, both alone and with the checkpoint inhibitors. Rodents treated with ALKS-4230 were seen to have lesser tumor growth and better survival, supporting clinical evaluation of ALKS 4230 as a potential immunotherapy in the oncology space. ALKS-4230 will be administered in combination with PD-1 inhibitor KEYTRUDA¬Æ (pembrolizumab). Pembrolizumab is an anti-PD-1 therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells, complimenting the mechanisms of action from ALKS-4230.  Alkermes has accelerated clinical evaluation of ALKS 4230 in combination with pembrolizumab based on data from the ongoing monotherapy dose-escalation stage of the phase 1 study, where ALKS 4230 demonstrated dose-dependent pharmacodynamic effects on circulating natural killer cells and CD8+ T cells, and minimal and non-dose dependent effects on immunosuppressive regulatory T cells.  

Initial data from Phase I is due in the second half of 2018, estimated to come out early November.


**Competition and Market:**

ALKS-4230 is a tough market, cancer is a hot sector but it continually sees failure.  While the FDA holds the stance that they want to try to push new oncology and immuno-oncology drugs through the approval process and get them to market to potentially save or extend lives, their decisions tend to skew otherwise.  Being so early on in development, it‚Äôs not necessary to dive into the market in depth as there is a large, unmet need in the oncology sector with the main focus being in immuno-oncology.

MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is overly crowded and overly competitive, surpassing 30 FDA approved products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is currently in an active transition where patents are expiring on top-selling products such as Eli Lilly's Cymbalta and Otsuka/BMS' Abilify, paving way for launches of Lundbeck/Takeda's Trintellix and Otsuka/Lundbeck's Rexulti.  These will create a significant growth in the market as cheaper generics will become available.  Growth in the MDD market is also expected to be driven by the potential introduction of numerous promising late-stage pipeline products into the market during the next few years which are directed at treatment-resistant patients.  These products include Alkermes' ALKS-5461, Allergan/Gedeon Richter/Mitsubishi Tanabe's Vraylar, Axsome Therapeutics' AXS-05, Janssen's esketamine, and Allergan's rapastinel.

MDD is the most common mental disorder in the U.S., affecting approximately 16 million American adults, of which about one-third remain untreated. The number of treated patients is projected to rise on account of expiring patents, the increase in available generic products, and rising awareness regarding depression and mental health issues.  This competitive market was priced at a massive $3.2 billion in 2015 and is expected to consistently grow at a CAGR of 6.1% until 2025 to reach $5.8 billion.  With the current social standings of mental health, students being required to take mandatory mental health courses now in many places, and social workers and therapists being more commonplace in schools and work places, we should see a larger surge in my opinion.  Growing female prevalence, increase in prescription spending, and escalating awareness of mental health will propel the growth of this market for many years to come.


**Financials:**

Alkermes has a great financial standing in the biotech industry.  Leveraging both their approved products and impressive collaborations, the company was able to boast a revenue growth of 39% ($304.6 million) through product sales and payments.  Many opportunities lined up for the company and set them up for success this second quarter. 

*Vivitrol sales increased 15% to $76.2 million

*Aristada sales increased 48% to $33.6 million

*Royalties from Johnson &amp; Johnson partnership increased 4% to $85.2 million

*Royalties from Acorda Therapeutics decreased 22% to $19.7 million

*License revenue from Biogen generated $48.3 million in revenue


Despite increased operation costs related to commercializing their products and further research and development, the company posted a Non-GAAP net income of $45.6 million and a Non-GAAP earnings per share of $0.29. With a total cash balance of $561 million and total debt of $280 million, the company stands on strong ground.  This second half of 2018 has several catalysts, combined with increasing revenues from collaborations and drug approvals, Alkermes is likely to see success, only to be complimented by hopefully positive data from their upcoming Phase I and PDUFA dates. The company is expecting to hit $1 billion in revenues for 2018 as a year, which would be a massive milestone for the pharmaceutical company.


**Review:**

Historically, the FDA has been flexible with depression medications, but failures will weigh Alkermes down.  Depression studies have had a flurry of failures over recent history, and failure here can dissuade further research in the pharmaceutical space until more is known on the biology side.  With over 30 currently approved products on the market for MDD, it is overly saturated and failure can spell the end for the drug.  Following their failures in FORWARD-3 and FORWARD-4, investors are weary of another failure, especially after the initial NDA was rejected.  Good news is, there is an advisory committee meeting in November to discuss ALKS-5461. In recent history, the FDA has gone against the decision and vote of the advisory committee only about 10% of the time over all, with 30% of the votes being against approving the drug and 70% of the votes being for approval.  Chances are from that perspective that the FDA will grant approval.  The compound also shows no suggestion of tolerance of therapeutic effects, the side effect profile was generally comparable to standard medications with no significant late appearing side effects, and when medication was halted there was no sign of opioid withdrawal.  With the competitive, growing market and patents expiring, a new and novel MDD treatment would be a value add.

In the case of the early stage ALKS-4230, oncology drug candidates historically have a 57% possibility of success moving from Phase I to Phase II compared to an industry average of 63.2% possibility of success.  This does shine in comparison to the oncology end success rate of a low 3.4%.  If I were to put my money where my mouth is, I am going with the data and not the suggestive words of the FDA to say that oncology might sound like a great industry with the backing of the FDA, but their actions prove otherwise.  Oncology drugs are more likely to be denied by the FDA and fail their clinical trials at much higher rates than other industries such as vaccines which show an end rate of success over 30%.  I would guess this drug might make it to Phase III with time, but statistically it is unlikely to see approval.  While Phase III or even Phase II are years away from completion, the data in Phase I will likely reveal a lot about the drug to make future estimations off of.  I see Phase I being positive.

Currently the stock is trading around $43 and showing a high level of support and consolidation in this zone.  With a high of over $70 not 7 months ago, the company is likely to recover and soar.  This stock does not take bad news well however, seeing several 10% or more drops over the past year, but never going under $40 for long.  I think between $42-46 are great entries for this stock.  Long term their finances are growing, increasing revenues from royalties and sales of their own approved products, on track to hit $1 billion in revenues this year, and a solid pipeline that shows great promise.  I would bank on good data from ALKS-4230 as well as a positive hearing from the advisory committee.  With the PDUFA date in January, we will see a heavy run up into the end of the year.  I would take advantage of this price entry for either a long-term hold or a swing trade.  I would predict levels of up to $55 in the coming 3 months.  


#**TLDR**

Shit will pop off in the next 3 months, I expect about 30-40% move by January 2019.  I am buying.
",2018-10-03 09:54:53,['ALKS']
0,Time to hop on the $BSTI train,Bouncing off of 52 week low. Rating to outperform from neutral. Couple reasons for this long downward trend. Essentially the trade war... which has very little effect on this company. Also shorts. Now is the time!,2018-10-03 18:16:39,['BSTI']
0,$WIN: Near pure arbitrage play for poor people who have patience . . . and want to make it rain,"If any of you fags can muster up some patience, there is a rare arbitrage opportunity in shares of $WIN, which is the result of some pricing disparities in the newly released Jan. 2021 options, combined with a very acute, and unexpected spike in implied volatility. The convergence of these 2 factors is allowing for some pretty ridiculous risk-reward profiles using a long collar strategy on $WIN shares.  

I opened the 2 positions below earlier today, and they are about as close as you can get to a pure arbitrage (i.e., completely risk-free) trade. To open a position, you buy the underlying $WIN shares, along with a Jan.21 option collar with a $5/$7 spread (buy the $5 put, and sell the $7 call).  Looks like there will still be good opportunities tomorrow to open these positions. 

&amp;#x200B;

**Position 1****:**

BUY - 10,000 Shares @ 5.06

BUY - 100 WIN Jan.21 $5.00 Puts @ $2.82

SELL - 100 WIN Jan.21 $7.00 Calls @ $2.84

(Net Collar Cost = -0.02 Credit)

**Position 2:**

BUY - 10,000 Shares @ 5.04

BUY - 100 WIN Jan.21 $5.00 Puts @ $2.66

SELL - 100 WIN Jan.21 $7.00 Calls @ $2.51

(Net Collar Cost = 0.15 Debit)

&amp;#x200B;

Basically, these trades are possible due to unusual disparity in put/call option pricing on the Jan.21 LEAPs, which allows you to initiate the collar at little or no cost. The end result is a long trade with substantial upside, and little to no downside exposure.  Both of my positions have upside of almost $2 per share, while limiting my maximum losses to just $0.04 per share for my first position, and $0.19 per share for my second position.  Here are the full risk-reward profiles for the 2 positions I opened today.  If you are using a margin account like I am, this strategy is absolutely cash-money since it costs practically nothing to open the position, but even with a cash account, this is still a compelling play. 

&amp;#x200B;

**Risk-Return Profile (Margin Account):**

*Position 1:*

Margin Required = $400

Max Gain = $1.96 per share ($19,600)

Max Loss = $0.04 per share ($400)

% Investment Return, Max Scenario = 4,900% 

*Position 2:*

Margin Required = $1,900

Max Gain = $1.81 per share ($18,100)

Max Loss = $0.19 per share ($1,900)

% Investment Return, Max Scenario = 952% 

&amp;#x200B;

**Risk-Return Profile (Cash Account):**

*Position 1:*

Cash Required = $50,400

Max Gain = $1.96 per share ($19,600)

Max Loss = $0.04 per share ($400)

% Investment Return, Max Scenario = 39% 

*Position 2:*

Cash Required = $51,900

Max Gain = $1.81 per share ($18,100)

Max Loss = $0.19 per share ($1,900)

% Investment Return, Max Scenario = 35% 

&amp;#x200B;

Note: I‚Äôm not getting into any serious diligence here on $WIN as a company. $WIN is a struggling telecom provider in the midst of a turn-around effort that management believes will restore profitability and cash flow.  The company‚Äôs future is uncertain ‚Äì it will either soar or sink in the next 3 years or so. Thanks to a successful debt restructuring earlier this year, the company‚Äôs near-term bond maturities have been pushed out to 2021, and the company‚Äôs cash flow is starting to improve. The key catalyst for the company will be the outcome of a litigation matter that went to trial this summer. It was a bond default dispute (Google it ‚Äì there are a million articles). The decision could come out any day, and if $WIN prevails (as most people expect), then we‚Äôre going to see $WIN shares double (or more) almost immediately. If the company loses, it may have to explore bankruptcy options or a white-knight sale of the company‚Äôs assets. The outcome of this trial will dictate whether this trade pays off at the maximum level, or whether it‚Äôs a write-off. I‚Äôm ball-parking the odds of a favorable decision at 80%.

&amp;#x200B;

&amp;#x200B;

Proof:

[https://imgur.com/a/z0wwXnE](https://imgur.com/a/z0wwXnE)

&amp;#x200B;

[https://imgur.com/a/IYOYdFu](https://imgur.com/a/IYOYdFu)

&amp;#x200B;

&amp;#x200B;",2018-10-03 22:49:48,['WIN']
0,"$GE puts giving me the long dong. 10/5, 10/12, and 10/19 $11.50 and $12 puts all gone to shit.",,2018-10-05 15:13:47,['GE']
0,When you long $Life and $Tsla and only one comes out on top,,2018-10-07 20:28:05,['L']
0,Long $XMAS - MarketWatch with the strong DD,,2018-10-09 11:46:07,['XMAS']
0,$ZNGA takeover interest,"Looks like I did spot something last week! 

Original post: [https://www.reddit.com/r/wallstreetbets/comments/9lo14d/znga\_high\_otm\_options\_volume/](https://www.reddit.com/r/wallstreetbets/comments/9lo14d/znga_high_otm_options_volume/)

Jumped by 12% today on takeover interest:

[https://www.marketwatch.com/story/zynga-jumps-after-report-of-takeover-interest-2018-10-09](https://www.marketwatch.com/story/zynga-jumps-after-report-of-takeover-interest-2018-10-09)

If it really was insider trading, then the pick of the 4.5 strike probably was not random. Earnings coming up and from what I've read takeover might happen before next earnings. Nov16 or Dec21 expirations look like the most promising.

I am long Dec21 4.5 calls. ",2018-10-09 18:19:53,['ZNGA']
0,"Long $BELTS, $PANTS and $ROPE",,2018-10-12 17:23:17,"['BELTS', 'PANTS']"
0,Free Tandem ($TNDM) Tendies,"Been long $TNDM since discovering DD from u/someroastedbeef a while back and have continued scooping up during this weeks slaughter.

Today Tandem Diabetes Care announced approval to market their t:slim X2 Insulin Pump in Canada. 

Lots of poutine-addicted Wilford Brimlies residing in North Mexico according the the official press release dropped after market close today.

""According to Diabetes Canada (www.diabetes.ca), there are more than 3.4 million Canadians living with diabetes, of which approximately 10 percent have type 1 diabetes""

Source: https://www.businesswire.com/news/home/20181012005460/en/Tandem-Diabetes-Care-Receives-Health-Canada-Approval

Earnings coming up 10/25 + international expansion = TNDM Tendies.",2018-10-12 20:22:26,['TNDM']
0,Long $NAP!,,2018-10-13 14:11:08,['NAP']
0,$DVMT. New Icahn letter to Dell.,"Carl Icahn just whipped out his fat 8.3 inch circumcised shlong and slapped Dell &amp; Friends again. 

I have no position in $DVMT stock (if you can even call it a stock) but I watch it. I agree with Icahn, that Dell and Co. have been trying to pull some bullshit again at the expense of regular shareholders who have rights to better more fair value and honest transparency from Dell management teams.

Here's the letter published this morning, reads just like he talks, might have wrote it himself:

https://carlicahn.com/carl-c-icahn-releases-open-letter-to-stockholders-of-dells-dvmt-tracking-stock/#_ftn1
",2018-10-15 08:02:35,['DVMT']
0,Long $TWLO,"Buy TWLO calls

Annual developer conference today and two new products Pay (securely process payments over phone w/Stripe being first partner) and AutoPilot (omnichannel bots) were introduced along with go live of flex platform which has oversubscribed demand

Guarantee you analysts will raise price targets tomorrow on the back of positive announcements at Signal conference. Pay partnership is with Stripe. Developers love Twilio

Stock has been hammered past two weeks due to global macro environment but fundamentals remain very strong

Twilio announced acquisition of sendgrid (leading email API platform) which basically rounds out the communications platform it offers. Email was the missing piece that people were wondering why Twilio doesn‚Äôt integrate and now they have it. Acquisition is via all-stock transaction. Despite this analysts remain bullish due to long term synergies and the fact that SendGrid userbase is different from Twilio‚Äôs which allows for cross selling opportunities 

Twilio build is a program for consulting/tech firms to help integrate Twilio with customers and spread awareness

Earnings date is scheduled for Nov 6 which is the day of the US house election. Twilio has developed an API for voting so there may be some parallels here between the two. 

Street Revenue estimates for Q3 aren‚Äôt even high and Twilio may blow past them given existing customers are spending more $ on increasing # of products 

TLDR: long TWLO calls expiring post earnings are the play here. Main risk is overall market selloff from worries around rising rates etc continuing causing tech shares to tumble further.  Twilio‚Äôs fundamentals are very strong and correction in past few weeks creates good buying opp. I also wrote a comment on here right before Q2 earnings predicting a major beat. ",2018-10-17 17:58:55,['TWLO']
0,If Anyone is feeling risky,"US-Traded China-Based Low Floats Stocks With Extreme Volatility: 

China Recycling Energy, $CREG 

ChinaCache, $CCIH 

JMU Limited, $JMU

Euro Tech, $CLWT

Takung Art, $TKAT

China Ceramics, $CCCL

Yulong Eco-Materials, $YECO

Delta Tech, $DELT

ChinaNet, $CNET

China TechFaith Wireless, $CNTF

China Advanced Construction $CADC",2018-10-18 10:46:15,"['CREG', 'CCIH', 'JMU', 'CLWT', 'TKAT', 'CCCL', 'YECO', 'DELT', 'CNET', 'CNTF', 'CADC']"
0,Long $BTC,,2018-10-22 21:18:52,['BTC']
0,Chai Peppermint L$TTe$,"I just witnessed two women walk into a Starbucks and order ""a tall chai latte with almond milk easy"" and ""a iced Caremel mocha extra sugar"" and then spend five minutes talking about their healthy water drinking habits. Long the white girl index.",2018-11-03 13:46:00,['TT']
0,Long $GNC,,2018-11-04 12:41:31,['GNC']
0,Long $GS,,2018-11-08 20:14:48,['GS']
0,Long $VKTX &amp; $SGMO,"$VKTX is super cheap. Trading at levels below the data release. Plus its part of the NASH hype.
$SGMO is down due to a delay in Hemo data they promised. Still believe its worth more due to it‚Äôs work in off-shelf car-t with Gilead.
Both are recommended by Shkreli as well.
",2018-11-09 14:54:43,['VKTX']
0,Long $XLNX! Massive 4% upside among Morgan Stanley‚Äôs TOP tech stock picks! Tendies here we go!! The autistic team at MS have done it again!,,2018-11-15 03:49:05,['XLNX']
0,"This is why PG&amp;E popped AH. Imho you should go with a delta/beta neutral approach if you‚Äôre going to play the $PCG game. Alternatively, go long and risk getting 3rd degree burns.",,2018-11-15 21:44:06,['PCG']
0,Long $BOSH,,2018-11-16 12:16:21,['BOSH']
0,Long $AMAZON :). Customer service is so good:),,2018-11-17 15:21:09,['AMAZON']
0,Long Nordstrom $JWN DD inside,"Literally, the DD is *inside*. Go to Nordstrom right now, it's not even Black Friday and I've never seen this many people in a store at once. It's so busy here it took 15 minutes to find a parking spot. Once inside, there was a live spinning DJ on the 3rd floor and a line to ride the escalator downstairs to a mob of shoppers around every attendant.

Those tax breaks are going to propel retail more than the seasonal adjustment average. After watching $JWN plummet double digits this past week, I'm making an earnings play next quarterly call and in the meantime buying longer term slightly OTM calls.

Do yourself a favor and go apply some mosaic theory and visit retail stores before and on and after Black Friday. They are stacking bills in here!",2018-11-17 16:28:40,['JWN']
0,Long $KSA big if true,,2018-11-22 17:54:27,['KSA']
0,"This ginger beer is good. Long $REED, DD inside",,2018-11-25 12:23:27,['REED']
0,Possible Market pattern,"So the past 2days ive been buyin 1 call of a cheap stock that was the biggest mover downwards on earning like totally shit the bed and buy the closest otm call i can the day of for either 1 or 2 month expiration, then wait and cash out. Yesterday was 50% on $GSM and today im up 75% on my CSH call, overreactions are easy money. Lets see how long i can ride the train, next stop the moonüöÄ",2018-11-28 17:12:46,['GSM']
0,Long $TITTIES,,2018-11-30 01:54:25,['TITTIES']
0,Long $GM,,2018-12-02 00:56:35,['GM']
0,"Long $MTCH, DD inside",,2018-12-04 18:40:32,['MTCH']
0,"Long $PM, DD inside","The whole market is red, so every trader's portfolios down. The depression from down 20% every day is turning people into chainsmokers. Long $PM",2018-12-07 10:18:02,['PM']
0,Long $UBER IPO (or short),,2018-12-09 14:57:47,['UBER']
0,$AMRN ~ Help me decide,"So as the title says. While I have my other money tied up in a Long position I want you guys to help me play with 500$ worth of options. Specifically Amarin. I've not yet tried Options. I expect them to go higher so I know calls is the way to go. But I'm not sure which ones to buy, so help me there or talk me out of them and into something else lol.
Thinking january or February to give them time to be.... *in the money*

https://imgur.com/a/p8KB2KG
",2018-12-10 19:45:13,['AMRN']
0,Only a fool seeks wisdom from a cookie. Real fortune comes in boxes of tendies. Long $CHKN,,2018-12-11 21:07:14,['CHKN']
0,"Guys, here is all the DD you need to go long on $YETI. Tendies in a Yeti are safe from bears.",,2018-12-14 17:30:31,['YETI']
0,Going long on $DS ‚õ≥Ô∏è,"So I‚Äôm sure everyone has heard of the popular Top Golf driving ranges that are popping up everywhere. If you‚Äôve ever been there without a reservation you‚Äôre waiting about 3 hours to get a bay. Drive shack is essentially the same thing and they are publicly traded. Coming up this spring they have locations opening up in Virginia, Florida and North Carolina. This place is a cash crop as it‚Äôs equipped with everything you need including heaters to keep it going year round and a perfect place for work events. Iv been to top golf a couple times and it‚Äôs always packed. Trading at about $4.25 I‚Äôm going to take a large position here and ride it out till spring when they open their new locations. ",2018-12-18 11:19:37,['DS']
0,Digital Ally $DGLY - Upcoming binary event,"Digital‚Äôs lawsuit against Axon is quickly approaching a jury trial.  If DGLY is victorious, which does not seem to be a long shot, DGLY will be receiving damage award in the tens of millions.  They were even talking about the possibility of 9 figures on the last conference call.  Plus they‚Äôre looking for a royalty on all the systems that Axon sells. 

There‚Äôs also a chance Axon settles, which would also cause a mooning event. 

If DGLY loses the lawsuit the company will go out of business for sure. 

Digital has only 10m shares float, market cap of 28m.   Average daily volume 44k shares.  

There are no options for this security.  This is a shares play.  Trust me, that‚Äôs probably a good thing for most of you. 







Axon just dropped their appeal",2018-12-20 13:17:01,['DGLY']
